share_log

Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target

Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target

奧本海默將 Diamedica Therapeutics 上調至跑贏大盤,宣佈目標股價爲7美元
Benzinga ·  2023/06/22 07:16

Oppenheimer analyst Francois Brisebois upgrades DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announces $7 price target.

奧本海默分析師弗朗索瓦·布里塞波瓦將Diamedica Therapeutics(納斯達克股票代碼:DMAC)從業績上調至跑贏大盤,並宣佈了7美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論